查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1472240

色素沉着治疗市场：按治疗类型、疾病类型和最终用户：2023-2032 年全球机会分析和产业预测

Hyperpigmentation Treatment Market By Treatment Type, By Disorder Type, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 270 Pages | 商品交期: 2-3个工作天内

价格

预计2022年全球色素沉着治疗市场将达51亿美元，2023年至2032年复合年增长率为7.5%，到2032年将达到105亿美元。

色素沉淀是一种皮肤病，其特征是皮肤特定区域变黑或变色。当负责肤色的黑色素过度产生并沉积在皮肤上时，就会发生这种现象。色素沉淀的原因有很多，包括黄褐斑、晒伤、发炎后色素沉淀和老龄化。有效的色素沉着管理通常包括使用局部治疗、雷射治疗、化学换肤，并且经常努力防晒以防止病情进一步恶化。

色素沉着过度治疗市场-IMG1

色素沉着治疗市场的成长归因于全球美容标准的变化和老年人口的快速成长。近年来，社会对美丽的认识发生了显着变化，洁净、均匀的肌肤变得更加重要。因此，人们都在努力追求更完美的肤色，导致对色素沉着治疗的需求不断增长。在媒体影响和社交平台普及的推动下，不断变化的美容标准创造了一种文化，将一尘不染的皮肤视为健康和吸引力的象征。随着人们寻求有效的解决方案来解决皮肤变色问题并实现所需的美感，这种文化转变导致色素沉着治疗的采用激增。因此，全球美容标准的变化预计将推动色素沉着治疗市场的成长。

此外，老年人口的快速成长预计也将显着促进市场成长。例如，美国人口普查局报告称，2020 年老年人口将达到 5,580 万人。随着世界人口结构的不断发展和老年人比例的增加，色素沉淀的发生率将变得更高。色素沉淀的特征是皮肤变黑，是老年人常见的皮肤病问题，通常是由于阳光照射、老龄化相关的变化和潜在的医疗状况等因素造成的。人口老化正在寻求改善皮肤外观和解决色素沉着不规则问题的解决方案，这推动了对先进和有针对性的色素沉着治疗的需求。製药和护肤行业开发了专门为满足老龄化人口的独特需求而设计的创新产品和治疗方法。然而，与化学换肤和光疗相关的副作用正在限制市场的成长。

色素沉着治疗市场按治疗类型、疾病类型、最终用户和地区进行细分。依治疗类型划分，市场分为外用製剂、光疗和微晶换肤。依疾病类型，市场分为老年斑​​、黄褐斑等。其他症状包括发炎后色素沉着和痤疮疤痕。依最终使用者分为医院、皮肤科诊所等。依地区划分，我们有北美（美国、加拿大、墨西哥）、欧洲（德国、法国、英国、义大利、西班牙、其他欧洲国家地区）、亚太地区（日本、中国、澳洲、印度、韩国、其他亚洲地区）太平洋地区）和拉丁美洲（巴西、哥伦比亚、阿根廷和其他拉丁美洲地区）和中东/非洲A（海湾合作委员会、南美、北非和其他中东/非洲A 地区）。

相关人员的主要利益

  • 该报告提供了 2022 年至 2032 年色素沉着治疗市场分析的细分市场、当前趋势、估计/趋势和动态的定量分析，并确定了主要的色素沉着治疗市场机会。
  • 我们提供市场研究以及与市场驱动因素、市场限制和市场机会相关的资讯。
  • 波特的五力分析揭示了买家和供应商的潜力，帮助相关人员做出利润驱动的业务决策并加强供应商和买家网路。
  • 对色素沉着治疗市场细分的详细分析有助于识别市场机会。
  • 每个地区的主要国家都根据其对全球市场的收益贡献绘製了地图。
  • 市场参与者定位有助于基准化分析，并提供对市场参与者当前位置的清晰了解。
  • 该报告包括对区域和全球色素沉着治疗市场趋势、主要企业、细分市场、应用领域和市场成长策略的分析。

可使用此报告进行客製化（请联络销售人员以了解额外费用和时间表）

  • 监管指引
  • 根据客户兴趣加入公司简介
  • 按国家或地区进行的附加分析 – 市场规模和预测
  • 公司简介的扩充列表
  • 历史市场资料
  • 主要参与者的详细资料（Excel格式，包括位置、联络资讯、供应商/供应商网路等）

目录

第一章简介

第 2 章执行摘要

第三章市场概况

  • 市场定义和范围
  • 主要发现
    • 主要影响因素
    • 关键投资机会
  • 波特五力分析
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会

第四章色素沉淀治疗市场：依治疗类型

  • 概述
  • 局部剂
  • 光疗
  • 微晶换肤

第五章色素沉着治疗市场：依疾病类型

  • 概述
  • 老人斑
  • 黄褐斑
  • 其他的

第六章色素沉淀治疗市场：依最终使用者分类

  • 概述
  • 医院
  • 皮肤科诊所
  • 其他的

第七章色素强化治疗市场：依地区

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
    • 哥伦比亚
    • 阿根廷
    • 其他拉丁美洲
  • 中东/非洲
    • GCC
    • 南非
    • 北非
    • 其他中东/非洲

第八章 竞争格局

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 2022年主要企业定位

第九章 公司简介

  • Episciences Inc
  • Vivier Pharma
  • Pierre Fabre SA
  • L'Oreal Group
  • Areolase Corporation
  • Lyma
  • Trophy Skin
  • Bio Italica
  • PCA Skin
  • Procter & Gamble
Product Code: A186336

The global hyperpigmentation treatment market was valued at $5.1 billion in 2022, and is projected to reach $10.5 billion by 2032, growing at a CAGR of 7.5% from 2023 to 2032. Hyperpigmentation is a dermatological condition characterized by the darkening or discoloration of certain areas of the skin. This phenomenon occurs when an excess amount of melanin, the pigment responsible for skin color, is produced and deposited in the skin. There are various causes of hyperpigmentation such as Melasma, sun exposure, post inflammatory hyperpigmentation, and age factor. Effective management of hyperpigmentation often involves the use of topical treatments, laser therapy, or chemical peels, along with diligent sun protection to prevent further exacerbation of the condition

Hyperpigmentation Treatment Market - IMG1

The hyperpigmentation treatment market growth is attributed to changes in beauty standards globally, and surge in geriatric population. In recent years, there has been a notable shift in societal perceptions of beauty, with an increasing emphasis on clear, even-toned skin. As a result, individuals are now more inclined toward achieving a flawless complexion, contributing to the heightened demand for hyperpigmentation treatments. The evolving beauty standards, fueled by media influence and the pervasive use of social platforms, have created a culture where blemish-free skin is considered a symbol of health and attractiveness. This cultural shift has led to a surge in the adoption of hyperpigmentation treatments as people seek effective solutions to address skin discoloration issues and attain the desired aesthetic. Thus, the change in beauty standards globally is expected to drive the growth of the hyperpigmentation treatment market.

In addition, the surge in geriatric population is expected to significantly contribute to the growth of the market. For instance, according to the U.S. Census Bureau, it was reported that the older population reached 55.8 million in 2020. As the global demographic landscape continues to evolve, with an increasing proportion of elderly individuals, the incidence of hyperpigmentation disorders becomes more prevalent. Hyperpigmentation, characterized by darkened areas of the skin, is a common dermatological concern among the elderly, often attributed to factors such as sun exposure, age-related changes, and underlying medical conditions. The geriatric population seeking solutions to enhance skin appearance and address pigmentation irregularities, has fueled the demand for advanced and targeted hyperpigmentation treatments. The pharmaceutical and skincare industries have developed innovative products and therapies specifically tailored to cater to the unique needs of the aging population. However, side effects associated with the chemical peels and photo therapy restrain the growth of the market.

The hyperpigmentation treatment market is segmented on the basis of treatment type, disorder type, end user, and region. By treatment type, the market is classified into topical agent, photo therapy, and microdermabrasion. By disorder type, the market is divided into age spots, melasma, and others. Others include post-inflammatory hyperpigmentation and acne scars. By end user, it is segregated into hospitals, dermatological clinics, and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), LA (Brazil, Colombia, Argentina, and rest of LA), and MEA (GCC, South Africa, North Africa, and rest of MEA).

Major key players that operate in the hyperpigmentation treatment market are Episciences Inc, Vivier Pharma, Pierre Fabre S.A, L'Oreal Paris, Areolase Corporation, Lyma, Trophy Skin, Bio Italica, PCA Skin and Procter & Gamble. Key players have adopted product launch as a key developmental strategy to improve the product portfolio of the hyperpigmentation treatment market

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hyperpigmentation treatment market analysis from 2022 to 2032 to identify the prevailing hyperpigmentation treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the hyperpigmentation treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global hyperpigmentation treatment market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Treatment Type

  • Topical Agent
  • Photo Therapy
  • Microdermabrasion

By Disorder Type

  • Age Spot
  • Melasma
  • Other

By End User

  • Hospitals
  • Dermatological clinics
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Colombia
    • Argentina
    • Rest Of La
  • Middle East and Africa
    • Gcc
    • South Africa
    • North Africa
    • Rest Of Mea

Key Market Players:

    • Episciences Inc
    • Vivier Pharma
    • Pierre Fabre S.A
    • L'Oreal Group
    • Areolase Corporation
    • Lyma
    • Trophy Skin
    • Bio Italica
    • PCA Skin
    • Procter & Gamble

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
  • 3.4. Market dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Topical Agent
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Photo Therapy
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Microdermabrasion
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Age Spot
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Melasma
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Other
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: HYPERPIGMENTATION TREATMENT MARKET, BY END USER

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospitals
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Dermatological clinics
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Others
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: HYPERPIGMENTATION TREATMENT MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by Treatment Type
    • 7.2.3. Market size and forecast, by Disorder Type
    • 7.2.4. Market size and forecast, by End User
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Market size and forecast, by Treatment Type
      • 7.2.5.1.2. Market size and forecast, by Disorder Type
      • 7.2.5.1.3. Market size and forecast, by End User
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Market size and forecast, by Treatment Type
      • 7.2.5.2.2. Market size and forecast, by Disorder Type
      • 7.2.5.2.3. Market size and forecast, by End User
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Market size and forecast, by Treatment Type
      • 7.2.5.3.2. Market size and forecast, by Disorder Type
      • 7.2.5.3.3. Market size and forecast, by End User
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by Treatment Type
    • 7.3.3. Market size and forecast, by Disorder Type
    • 7.3.4. Market size and forecast, by End User
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Market size and forecast, by Treatment Type
      • 7.3.5.1.2. Market size and forecast, by Disorder Type
      • 7.3.5.1.3. Market size and forecast, by End User
      • 7.3.5.2. France
      • 7.3.5.2.1. Market size and forecast, by Treatment Type
      • 7.3.5.2.2. Market size and forecast, by Disorder Type
      • 7.3.5.2.3. Market size and forecast, by End User
      • 7.3.5.3. UK
      • 7.3.5.3.1. Market size and forecast, by Treatment Type
      • 7.3.5.3.2. Market size and forecast, by Disorder Type
      • 7.3.5.3.3. Market size and forecast, by End User
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Market size and forecast, by Treatment Type
      • 7.3.5.4.2. Market size and forecast, by Disorder Type
      • 7.3.5.4.3. Market size and forecast, by End User
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Market size and forecast, by Treatment Type
      • 7.3.5.5.2. Market size and forecast, by Disorder Type
      • 7.3.5.5.3. Market size and forecast, by End User
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Market size and forecast, by Treatment Type
      • 7.3.5.6.2. Market size and forecast, by Disorder Type
      • 7.3.5.6.3. Market size and forecast, by End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by Treatment Type
    • 7.4.3. Market size and forecast, by Disorder Type
    • 7.4.4. Market size and forecast, by End User
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Market size and forecast, by Treatment Type
      • 7.4.5.1.2. Market size and forecast, by Disorder Type
      • 7.4.5.1.3. Market size and forecast, by End User
      • 7.4.5.2. China
      • 7.4.5.2.1. Market size and forecast, by Treatment Type
      • 7.4.5.2.2. Market size and forecast, by Disorder Type
      • 7.4.5.2.3. Market size and forecast, by End User
      • 7.4.5.3. India
      • 7.4.5.3.1. Market size and forecast, by Treatment Type
      • 7.4.5.3.2. Market size and forecast, by Disorder Type
      • 7.4.5.3.3. Market size and forecast, by End User
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Market size and forecast, by Treatment Type
      • 7.4.5.4.2. Market size and forecast, by Disorder Type
      • 7.4.5.4.3. Market size and forecast, by End User
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Market size and forecast, by Treatment Type
      • 7.4.5.5.2. Market size and forecast, by Disorder Type
      • 7.4.5.5.3. Market size and forecast, by End User
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Market size and forecast, by Treatment Type
      • 7.4.5.6.2. Market size and forecast, by Disorder Type
      • 7.4.5.6.3. Market size and forecast, by End User
  • 7.5. Latin America
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by Treatment Type
    • 7.5.3. Market size and forecast, by Disorder Type
    • 7.5.4. Market size and forecast, by End User
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Market size and forecast, by Treatment Type
      • 7.5.5.1.2. Market size and forecast, by Disorder Type
      • 7.5.5.1.3. Market size and forecast, by End User
      • 7.5.5.2. Colombia
      • 7.5.5.2.1. Market size and forecast, by Treatment Type
      • 7.5.5.2.2. Market size and forecast, by Disorder Type
      • 7.5.5.2.3. Market size and forecast, by End User
      • 7.5.5.3. Argentina
      • 7.5.5.3.1. Market size and forecast, by Treatment Type
      • 7.5.5.3.2. Market size and forecast, by Disorder Type
      • 7.5.5.3.3. Market size and forecast, by End User
      • 7.5.5.4. Rest Of La
      • 7.5.5.4.1. Market size and forecast, by Treatment Type
      • 7.5.5.4.2. Market size and forecast, by Disorder Type
      • 7.5.5.4.3. Market size and forecast, by End User
  • 7.6. Middle East and Africa
    • 7.6.1. Key market trends, growth factors and opportunities
    • 7.6.2. Market size and forecast, by Treatment Type
    • 7.6.3. Market size and forecast, by Disorder Type
    • 7.6.4. Market size and forecast, by End User
    • 7.6.5. Market size and forecast, by country
      • 7.6.5.1. Gcc
      • 7.6.5.1.1. Market size and forecast, by Treatment Type
      • 7.6.5.1.2. Market size and forecast, by Disorder Type
      • 7.6.5.1.3. Market size and forecast, by End User
      • 7.6.5.2. South Africa
      • 7.6.5.2.1. Market size and forecast, by Treatment Type
      • 7.6.5.2.2. Market size and forecast, by Disorder Type
      • 7.6.5.2.3. Market size and forecast, by End User
      • 7.6.5.3. North Africa
      • 7.6.5.3.1. Market size and forecast, by Treatment Type
      • 7.6.5.3.2. Market size and forecast, by Disorder Type
      • 7.6.5.3.3. Market size and forecast, by End User
      • 7.6.5.4. Rest Of Mea
      • 7.6.5.4.1. Market size and forecast, by Treatment Type
      • 7.6.5.4.2. Market size and forecast, by Disorder Type
      • 7.6.5.4.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product mapping of top 10 player
  • 8.4. Competitive dashboard
  • 8.5. Competitive heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Episciences Inc
    • 9.1.1. Company overview
    • 9.1.2. Key executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Vivier Pharma
    • 9.2.1. Company overview
    • 9.2.2. Key executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. Pierre Fabre S.A
    • 9.3.1. Company overview
    • 9.3.2. Key executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. L'Oreal Group
    • 9.4.1. Company overview
    • 9.4.2. Key executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. Areolase Corporation
    • 9.5.1. Company overview
    • 9.5.2. Key executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. Lyma
    • 9.6.1. Company overview
    • 9.6.2. Key executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. Trophy Skin
    • 9.7.1. Company overview
    • 9.7.2. Key executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. Bio Italica
    • 9.8.1. Company overview
    • 9.8.2. Key executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
    • 9.8.7. Key strategic moves and developments
  • 9.9. PCA Skin
    • 9.9.1. Company overview
    • 9.9.2. Key executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
    • 9.9.7. Key strategic moves and developments
  • 9.10. Procter & Gamble
    • 9.10.1. Company overview
    • 9.10.2. Key executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance
    • 9.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 02. HYPERPIGMENTATION TREATMENT MARKET FOR TOPICAL AGENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. HYPERPIGMENTATION TREATMENT MARKET FOR PHOTO THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. HYPERPIGMENTATION TREATMENT MARKET FOR MICRODERMABRASION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 06. HYPERPIGMENTATION TREATMENT MARKET FOR AGE SPOT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. HYPERPIGMENTATION TREATMENT MARKET FOR MELASMA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. HYPERPIGMENTATION TREATMENT MARKET FOR OTHER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. GLOBAL HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 10. HYPERPIGMENTATION TREATMENT MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. HYPERPIGMENTATION TREATMENT MARKET FOR DERMATOLOGICAL CLINICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. HYPERPIGMENTATION TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. HYPERPIGMENTATION TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA HYPERPIGMENTATION TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 18. U.S. HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 19. U.S. HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 20. U.S. HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 21. CANADA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 22. CANADA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 23. CANADA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 24. MEXICO HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 27. EUROPE HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE HYPERPIGMENTATION TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 31. GERMANY HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 32. GERMANY HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 33. GERMANY HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 36. FRANCE HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 37. UK HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 38. UK HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 39. UK HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 40. ITALY HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 41. ITALY HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 42. ITALY HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 45. SPAIN HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 46. REST OF EUROPE HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 47. REST OF EUROPE HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 48. REST OF EUROPE HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 49. ASIA-PACIFIC HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 50. ASIA-PACIFIC HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC HYPERPIGMENTATION TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 53. JAPAN HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 54. JAPAN HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 55. JAPAN HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 56. CHINA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 57. CHINA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 58. CHINA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 59. INDIA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 60. INDIA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 61. INDIA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 62. AUSTRALIA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 63. AUSTRALIA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 64. AUSTRALIA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH KOREA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH KOREA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH KOREA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 71. LATIN AMERICA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 72. LATIN AMERICA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 73. LATIN AMERICA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 74. LATIN AMERICA HYPERPIGMENTATION TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 75. BRAZIL HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 76. BRAZIL HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 77. BRAZIL HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 78. COLOMBIA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 79. COLOMBIA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 80. COLOMBIA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 81. ARGENTINA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 82. ARGENTINA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 83. ARGENTINA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 84. REST OF LA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 85. REST OF LA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 86. REST OF LA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 87. MIDDLE EAST AND AFRICA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 88. MIDDLE EAST AND AFRICA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 89. MIDDLE EAST AND AFRICA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 90. MIDDLE EAST AND AFRICA HYPERPIGMENTATION TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 91. GCC HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 92. GCC HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 93. GCC HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 94. SOUTH AFRICA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 95. SOUTH AFRICA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 96. SOUTH AFRICA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 97. NORTH AFRICA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 98. NORTH AFRICA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 99. NORTH AFRICA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 100. REST OF MEA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 101. REST OF MEA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 102. REST OF MEA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 103. EPISCIENCES INC: KEY EXECUTIVES
  • TABLE 104. EPISCIENCES INC: COMPANY SNAPSHOT
  • TABLE 105. EPISCIENCES INC: PRODUCT SEGMENTS
  • TABLE 106. EPISCIENCES INC: SERVICE SEGMENTS
  • TABLE 107. EPISCIENCES INC: PRODUCT PORTFOLIO
  • TABLE 108. EPISCIENCES INC: KEY STRATERGIES
  • TABLE 109. VIVIER PHARMA: KEY EXECUTIVES
  • TABLE 110. VIVIER PHARMA: COMPANY SNAPSHOT
  • TABLE 111. VIVIER PHARMA: PRODUCT SEGMENTS
  • TABLE 112. VIVIER PHARMA: SERVICE SEGMENTS
  • TABLE 113. VIVIER PHARMA: PRODUCT PORTFOLIO
  • TABLE 114. VIVIER PHARMA: KEY STRATERGIES
  • TABLE 115. PIERRE FABRE S.A: KEY EXECUTIVES
  • TABLE 116. PIERRE FABRE S.A: COMPANY SNAPSHOT
  • TABLE 117. PIERRE FABRE S.A: PRODUCT SEGMENTS
  • TABLE 118. PIERRE FABRE S.A: SERVICE SEGMENTS
  • TABLE 119. PIERRE FABRE S.A: PRODUCT PORTFOLIO
  • TABLE 120. PIERRE FABRE S.A: KEY STRATERGIES
  • TABLE 121. L'OREAL GROUP: KEY EXECUTIVES
  • TABLE 122. L'OREAL GROUP: COMPANY SNAPSHOT
  • TABLE 123. L'OREAL GROUP: PRODUCT SEGMENTS
  • TABLE 124. L'OREAL GROUP: SERVICE SEGMENTS
  • TABLE 125. L'OREAL GROUP: PRODUCT PORTFOLIO
  • TABLE 126. L'OREAL GROUP: KEY STRATERGIES
  • TABLE 127. AREOLASE CORPORATION: KEY EXECUTIVES
  • TABLE 128. AREOLASE CORPORATION: COMPANY SNAPSHOT
  • TABLE 129. AREOLASE CORPORATION: PRODUCT SEGMENTS
  • TABLE 130. AREOLASE CORPORATION: SERVICE SEGMENTS
  • TABLE 131. AREOLASE CORPORATION: PRODUCT PORTFOLIO
  • TABLE 132. AREOLASE CORPORATION: KEY STRATERGIES
  • TABLE 133. LYMA: KEY EXECUTIVES
  • TABLE 134. LYMA: COMPANY SNAPSHOT
  • TABLE 135. LYMA: PRODUCT SEGMENTS
  • TABLE 136. LYMA: SERVICE SEGMENTS
  • TABLE 137. LYMA: PRODUCT PORTFOLIO
  • TABLE 138. LYMA: KEY STRATERGIES
  • TABLE 139. TROPHY SKIN: KEY EXECUTIVES
  • TABLE 140. TROPHY SKIN: COMPANY SNAPSHOT
  • TABLE 141. TROPHY SKIN: PRODUCT SEGMENTS
  • TABLE 142. TROPHY SKIN: SERVICE SEGMENTS
  • TABLE 143. TROPHY SKIN: PRODUCT PORTFOLIO
  • TABLE 144. TROPHY SKIN: KEY STRATERGIES
  • TABLE 145. BIO ITALICA: KEY EXECUTIVES
  • TABLE 146. BIO ITALICA: COMPANY SNAPSHOT
  • TABLE 147. BIO ITALICA: PRODUCT SEGMENTS
  • TABLE 148. BIO ITALICA: SERVICE SEGMENTS
  • TABLE 149. BIO ITALICA: PRODUCT PORTFOLIO
  • TABLE 150. BIO ITALICA: KEY STRATERGIES
  • TABLE 151. PCA SKIN: KEY EXECUTIVES
  • TABLE 152. PCA SKIN: COMPANY SNAPSHOT
  • TABLE 153. PCA SKIN: PRODUCT SEGMENTS
  • TABLE 154. PCA SKIN: SERVICE SEGMENTS
  • TABLE 155. PCA SKIN: PRODUCT PORTFOLIO
  • TABLE 156. PCA SKIN: KEY STRATERGIES
  • TABLE 157. PROCTER & GAMBLE: KEY EXECUTIVES
  • TABLE 158. PROCTER & GAMBLE: COMPANY SNAPSHOT
  • TABLE 159. PROCTER & GAMBLE: PRODUCT SEGMENTS
  • TABLE 160. PROCTER & GAMBLE: SERVICE SEGMENTS
  • TABLE 161. PROCTER & GAMBLE: PRODUCT PORTFOLIO
  • TABLE 162. PROCTER & GAMBLE: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. HYPERPIGMENTATION TREATMENT MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF HYPERPIGMENTATION TREATMENT MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN HYPERPIGMENTATION TREATMENT MARKET
  • FIGURE 04. TOP INVESTMENT POCKETS IN HYPERPIGMENTATION TREATMENT MARKET (2023-2032)
  • FIGURE 05. BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. BARGAINING POWER OF BUYERS
  • FIGURE 07. THREAT OF SUBSTITUTION
  • FIGURE 08. THREAT OF SUBSTITUTION
  • FIGURE 09. COMPETITIVE RIVALRY
  • FIGURE 10. GLOBAL HYPERPIGMENTATION TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF HYPERPIGMENTATION TREATMENT MARKET FOR TOPICAL AGENT, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF HYPERPIGMENTATION TREATMENT MARKET FOR PHOTO THERAPY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF HYPERPIGMENTATION TREATMENT MARKET FOR MICRODERMABRASION, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF HYPERPIGMENTATION TREATMENT MARKET FOR AGE SPOT, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF HYPERPIGMENTATION TREATMENT MARKET FOR MELASMA, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF HYPERPIGMENTATION TREATMENT MARKET FOR OTHER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF HYPERPIGMENTATION TREATMENT MARKET FOR HOSPITALS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF HYPERPIGMENTATION TREATMENT MARKET FOR DERMATOLOGICAL CLINICS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF HYPERPIGMENTATION TREATMENT MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 23. HYPERPIGMENTATION TREATMENT MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 24. U.S. HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. CANADA HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. MEXICO HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. GERMANY HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. FRANCE HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. UK HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. ITALY HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. SPAIN HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. REST OF EUROPE HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. JAPAN HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. CHINA HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. INDIA HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. AUSTRALIA HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. SOUTH KOREA HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. REST OF ASIA-PACIFIC HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. BRAZIL HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. COLOMBIA HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. ARGENTINA HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. REST OF LA HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. GCC HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 44. SOUTH AFRICA HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 45. NORTH AFRICA HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 46. REST OF MEA HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 47. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 48. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 49. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 50. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 51. COMPETITIVE DASHBOARD
  • FIGURE 52. COMPETITIVE HEATMAP: HYPERPIGMENTATION TREATMENT MARKET
  • FIGURE 53. TOP PLAYER POSITIONING, 2022